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Summary The cytotoxic and cytostatic responses of peripheral blood lymphocytes from eight cancer patients
and splenocytes from four patients activated with rIL2 and a combination of rIL2 and rTNF-alpha were
tested against two tumour cell lines. The cytotoxic response of rIL2-activated lymphocytes did not exceed the
natural killer cytotoxicity values in all patients tested. In fact the killing capacity of some PBL deteriorated
after rIL2 activation. The combined use of rIL2 and rTNF-alpha reversed this detrimental effect and
enhanced the cytotoxic capacity of all PBL tested. In instances where high levels of killing were already
achieved by rIL2 alone additional rTNF-alpha did not induce a significant change. This indicates that the role
of rTNF-alpha may be to promote the response to rIL2 of PBL which react suboptimally to this lymphokine.
rTNF-alpha did not only enhance cytotoxic capacity but also conferred cytostatic capacity to rIL2-activated
LAK cells which were cytotoxic but unable to inhibit the growth of the surviving target cells. Natural killer
cell selected K562 target cells which were less susceptible to killing by untreated lymphocytes than the parent
K562 tumour cell line were killed more aggressively by rIL2+ rTNF-alpha LAK cells than by rIL2-LAK cells.
No phenotypic differences were detected in these two cultures of LAK cells which indicates that the increased
cytotoxic and cytostatic capacity of rIL2+rTNF-alpha-LAK cells may be due to a higher state of activation
of these cells or due to their capacity to recognise a broader spectrum of targets than rIL2-LAK cells.
The use of recombinant interleukin-2 (rIL2) in the activation
of non-specific killer cells with the capacity to lyse natural-
killer (NK) resistant tumour cells has been extensively
analysed (Grimm et al., 1982, 1983; Muul et al., 1986). Such
cells, designated lymphokine-activated killer (LAK) cells,
have been used for immunotherapy of cancer patients when
combined with in vivo administration of IL2 (Rosenberg et
al., 1985, 1987). The results of these human trials indicated
that further work to increase the therapeutic effects and
reduce the toxicity of this treatment is necessary. These
goals may be achieved either by increasing the numbers or
the cytotoxic potency of LAK cells administered combined
with lower doses of rIL2. Recent experiments have
demonstrated that activating peripheral blood lymphocytes
(PBL) with anti-CD3 monoclonal antibody and rIL2 resulted
in 1,000-fold expansion of LAK cell numbers. However, this
required a culture period of 21 days and there was loss of
LAK activity during the initial 12 days of culture (Ochoa et
al., 1987). These workers also demonstrated that the
exogenous addition of beta-interleukin 1, interferon-beta or
interferon-gamma can augment the lytic activity of cell
populations expanded by anti-CD3 plus rIL2.
In this report we examined the capacity of recombinant
tumour necrosis factor-alpha (rTNF-alpha) to enhance the
lytic activity of rIL2-activated PBL in a 3-5 day in vitro
culture system. The biological effects of TNF, previously
known as cachectin (Beutler & Cerami, 1986) are diverse.
Suppression of lipoprotein lipase activity enhancement of
prostaglandin E2 and collagenase production by synovial
cells and dermal fibroblasts, stimulation of bone resorption
by osteoclasts and stimulation of procoagulant activity by
vascular endothelial cells are amongst the spectrum of TNF
induced events (Torti et al., 1985; Dayer et al., 1985;
Bertolini et al., 1986; Nawroth & Stern, 1986). The latter
phenomenon which can cause vascular thrombosis and
ischaemia of solid tumours has been associated with the
antitumour actions of rTNF-alpha (Palladino et al., 1987).
rTNF-alpha is also directly cytotoxic for some human
tumour cell lines and cytostatic or stimulatory for others but
has no direct action on several tumour cells (Williamson et
al., 1983; Sugarman et al., 1985; Ruggiero et al., 1987).
The present study demonstrates that rTNF-alpha can also
exert antitumour effects via its action on rIL2-activated
LAK cells. rTNF-alpha added with rIL2 to a culture of PBL
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enhanced both the cytolytic and cytostatic effects of the
resultant LAK cells within 3-5 days. Furthermore, natural
killer (NK) cell resistant K562 target cells which grew out
after one cycle of NK cell killing were considerably less
resistant to rIL2+rTNF-alpha activated LAK cells than to
those activated with rIL2 alone.
Materials and methods
Peripheral blood lymphocytes and spleen cells
Forty millilitres of venous blood from cancer patients was
collected in heparinised tubes and diluted with RPMI 1640
(Gibco). The lymphocytes were separated by barrier centri-
fugation, washed in RPMI and cryopreserved in liquid
nitrogen for future use. Fragments were taken from spleens
removed during resection for gastro-oesophageal and
pancreatic carcinoma. These were forced through stainless
steel mesh sieves to obtain single cell suspensions. The cells
were washed in RPMI and cryopreserved.
Generation of lymphokine activated killer cells
Peripheral blood lymphocytes were removed from liquid
nitrogen, washed and resuspended at a concentration of
1 x 106 ml - in RPMI 1640 containing 10% fetal calf serum
and antibiotics. Aliquots were cultured at 37°C in a 5% CO2
atmosphere in the presence of 100unitsml-1 recombinant
human interleukin-2 (rhIL2) (Biogen) or a combination of
100unitsml- rhIL2 and 100unitsml-1 recombinant human
tumour necrosis factor-alpha (rhTNF-alpha) (Asahi
Chemical Industry Co. Ltd, London).
Cytotoxic assay
Untreated lymphocytes or splenocytes and samples cultured
for 3-5 days were tested for the capacity to kill the tumour
target cell lines K562 (erythroleukaemia) and MPCa
(pancreatic carcinoma). The target cell lines were maintained
by twice weekly passage in RPMI 1640 containing 10% FCS
and antibiotics. On the day of the assay 1-2 x 106 target cells
suspended in 200pl of culture medium were radiolabelled
with 2004uCi of 5ICr-sodium chromate (Amersham) for 2h
at 37TC with occasional shaking. The cells were washed three
times and counted. Effector cells washed and resuspended in
culture medium were mixed with 2 x 104 target cells at
effector to target ratios of 5:1 and 2.5: 1 in a total volume of
200,ul in V bottom 96-well plates. The target cells were also
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incubated in medium alone and with 2% Triton-X for
estimations of spontaneous and maximum release of isotope.
The plates were incubated for 18 h at 37°C in a 5% CO2
atmosphere, 100,l of supernatant were then removed from
each well for isotope counting. Percentage-specific release of
51Cr was calculated according to the formula
specific 51Cr release
c.p.m. test - c.p.m. spontaneous
c.p.m. maximum - c.p.m. spontaneous
x 100
Cytostasis assay
After removal of supernatants from the plates set up for the
cytotoxicity assay the wells were replenished with 100pI of
culture medium and incubated for a further 24h. One ,Ci
3H-thymidine (Amersham) was then added to each well
apart from those treated with Triton-X. The plates were
reincubated overnight and then harvested on filter paper
strips. Uptake of radioisotope was measured in a
scintillation counter. Inhibition of tumour growth of cyto-
stasis was calculated according to the following formula
% inhibition
100- c.p.m. tumour cells in presence ofeffectors 100
c.p.m. tumour cells alone
Isotope taken up by the effectors alone was ignored in the
calculation of these results as these counts were only a small
proportion of the total uptake by tumour cells alone.
Selection of natural killer (NK) resistant K562 tumour
cell line
Untreated splenic lymphocytes were mixed with K562 target
cells at a ratio of 10:1. The mixture was gently centrifuged
and incubated for 18h at 37°C in a 5% CO2 atmosphere.
The pellet was then dispersed in fresh culture medium and
incubated until the viable K562 cells populated the flask.
These cells were called natural killer cell selected (NKCS)
and were maintained in culture alongside the parent K562
cell line.
Results
Examination of the development of cytotoxic activity in PBL
from cancer patients in response to rIL2 and a combination
of rIL2 and rTNF-alpha
Peripheral blood lymphocytes from eight randomly selected
cancer patients were removed from liquid nitrogen storage
and tested for their capacity to kill 51Cr-labelled K562 and
MPCa target cells. Percentage specific release of 51Cr ranged
from 16.9 to 52.4% for the K562 targets at an effector to
target ratio of 5:1 while at the same time E:T ratio specific
killing ofMPCa targets ranged from - 1.2 to 17.5% (Table I).
The response to IL2 of the PBL from the eight patients
tested was not uniform. Cytotoxicity against K562 increased
in three patients (nos 1, 4 and 7) by 60 to over 300% above
the natural killer cytotoxicity values. The levels of killing
remained almost unchanged in two patients (nos 5 and 8),
while there was a considerable decrease in the cytotoxic
capacity of PBL from the remaining three patients (nos 2, 3
and 6) after rIL2 activation. Cytotoxicity against MPCa
increased 2-20-fold in six patients (nos 1, 4-8), remained
stable in one (no. 2) and decreased in one (no. 3) (Table I).
The use of a combination of rIL2 and rTNF-alpha for
activation resulted in the development of higher cytotoxic
capacity by PBL from all patients tested compared to their
non-activated or rIL2-activated counterparts. In one instance
where a high level of killing was already achieved using rIL2
alone (patient no. 2), the level of specific killing did not
change significantly by the addition of rTNF-alpha. The
effect of rTNF-alpha was most pronounced on the PBL
which did not develop high levels of killing due to rIL2
activation (Table I).
Development of cytostatic activity of PBL treated with rIL2
and a combination of rIL2 and rTNF-alpha
On completion of the cytotoxicity assays the capacity of the
effector cells to inhibit the growth of the surviving tumour
target cells was examined. The results in Table II
demonstrate that there was no correlation between the levels
of cytotoxicity and cytostasis achieved by the untreated PBL.
In spite of reasonable levels of natural killer activity in all
test samples, cytostatic activity was present only in two
against the K562 targets and in five against MPCa targets.
Activation with rIL2 generated some cytostatic activity
against K562 in all but two PBL samples. In these two
samples (nos 3 and 7) the activated cells developed the
capacity to stimulate the growth of K562 in spite of the fact
that in patient no. 7 the cytotoxic activity of rIL2-activated
LAK cells against this tumour was over 80%. rIL2
activation of PBL from patient no. 3 was detrimental to
both cytotoxic and cytostatic responses.
The cytostatic activity against MPCa targets of all PBL
samples increased 2-4-fold by rIL2 activation. Some samples
(nos 4, 5 and 7), which had a pronounced stimulatory effect
on these tumour cells, also became strongly inhibitory (Table
II). The addition of rTNF-alpha to the activation cultures of
the effector cells did not make a significant difference to the
improved levels of cytostasis against MPCa achieved by PBL
activated with rIL2 alone. Cytostasis against K562, however,
was greatly improved when the lymphocytes were activated
with rIL2 and rTNF-alpha. The detrimental effects of rIL2
activation on the cytostatic capacity of lymphocytes from
patients 3 and 7 were reversed with the additional use of
rTNF-alpha and the cytostatic capacity of lymphocytes from
the remaining patients increased 2-6-fold (Table II).
Table I Cytotoxic activity of PBL and LAK cells from eight randomly selected cancer patients against two
tumour cell lines
Treatment ofperipheral blood lymphocytes (% specific
51Cr-releasefrom targets at effector to target ratios)
Nil rIL2 rIL2+rTNF-a
K562 MPCa K562 MPCa K562 MPCa
Patient no. 5:1 2.5:1 5:1 2.5:1 5:1 2.5:1 5:1 2.5:1 5:1 2.5:1 5:1 2.5:1
1 36.2 24.2 16.0 9.4 64.6 40.1 33.0 25.5 76.3 65.4 64.7 65.1
2 21.1 16.5 13.4 10.1 15.0 8.6 13.4 11.0 49.6 33.1 50.3 38.2
3 19.9 9.7 6.9 4.9 6.0 4.0 3.1 5.5 42.3 24.6 50.6 37.4
4 16.9 18.3 9.6 10.1 55.2 30.7 31.1 21.6 66.4 42.0 58.5 41.1
5 48.8 26.3 17.5 9.7 40.6 26.0 33.0 23.8 62.0 44.3 61.7 48.6
6 25.8 19.3 8.2 4.9 18.5 9.2 13.9 8.2 68.8 54.8 64.7 47.1
7 52.4 19.1 10.4 7.0 82.8 64.7 54.0 36.5 76.8 71.6 78.5 73.3
8 21.5 9.2 -1.2 2.6 22.7 13.0 21.5 16.4 76.9 56.9 62.0 54.3
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Table II Cytostatic activity of untreated PBL and LAK cells from eight randomly selected cancer patients against two
tumour cell lines
Treatment ofperipheral blood lymphocytes (% inhibition
of 3H-thymidine uptake by targets at effector to target ratios)
Nil rIL2 rIL2+rTNF-a
K562 MPCa K562 MPCa K562 MPCa
Patient no. 5:1 2.5:1 5:1 2.5:1 5:1 2.5:1 5:1 2.5:1 5:1 2.5:1 5:1 2.5:1
1 -1.6 12.2 10.3 10.1 14.1 8.4 29.7 34.0 22.7 38.4 46.6 43.0
2 -2.4 1.1 33.7 23.6 2.9 11.5 15.3 38.8 17.9 33.0 32.8 48.1
3 -11.7 9.1 3.4 24.2 -47.8 23.3 24.4 21.7 26.0 40.7 31.1 58.4
4 -11.7 -18.3 -35.1 -1.0 8.3 27.7 35.0 30.0 30.5 29.6 29.8 38.2
5 -5.3 19.6 -12.9 12.2 15.7 4.0 38.0 44.2 30.8 17.8 38.4 62.6
6 21.9 10.2 14.5 21.2 33.4 14.0 37.2 29.4 36.2 32.1 45.1 39.3
7 4.7 -3.0 -11.0 2.8 -13.1 10.5 24.5 25.0 13.0 39.8 33.0 49.0
8 18.1 29.5 12.3 19.0 5.7 32.8 29.7 28.8 35.9 37.2 43.6 39.0
Table III Cytotoxic activity of untreated splenic lymphocytes and splenic LAK cells
from four cancer patients against two tumour cell lines
% specific 51Cr-release from target cells at effector to target ratios
Treatment K562 MPCa K562 MPCa
ofsplenic
lymphocytes 5:1 2.5:1 5:1 2.5:1 5:1 2.5:1 5:1 2.5:1
Patient I Patient 2
Nil 20.6 13.2 23.0 22.6 27.0 18.5 18.5 8.8
rIL2 45.5 13.7 50.7 46.5 46.5 30.6 30.1 16.0
rIL2+rTNF-a 81.4 65.0 37.0 23.7 55.5 36.0 33.7 27.4
Patient 3 Patient 4
Nil 45.0 28.8 52.3 38.7 59.3 35.0 67.0 43.1
rIL2 94.6 85.5 71.9 74.5 90.7 68.2 79.8 65.5
rIL2+rTNF-a 85.6 79.0 70.3 45.0 85.7 71.3 77.3 64.7
Generation of cytotoxic activity in splenic lymphocytes using
rIL2 and rTNF-alpha
The potential development of LAK activity from splenocytes
was examined using cells from four spleens removed during
surgical resection for gastro-oesophageal and pancreatic
carcinoma. Untreated splenocytes from two patients had low
cytotoxic activity against K562 and MPCa ranging from 18.5
to 27%, while splenocytes from the remaining two patients
achieved levels of killing ranging from 45 to 67% (Table III).
Activation with rIL2 increased the cytotoxic capacity of the
splenocytes from the former two patients to the range 30-
45% and the latter to 72-95%. Preincubation of the spleno-
cytes with additional rTNF-alpha did not confer further
improvement to the latter group but significantly improved
the cytotoxic potential of the former group with levels of
killing within the range 33-81% (Table III).
Cytotoxicity of LAK cells against NK-resistant K562 targets
K562 target cells which survived cytotoxicity by NK cells in
a preparative assay were allowed to grow in culture and were
used as target cells to test the cytotoxic capacity of LAK
cells activated with rIL2 or a combination of rIL2 and
rTNF-alpha. Results in Table IV demonstrate that one cycle
of NK selection of K562 leukaemic cells increases the
resistance of these cells to a subsequent NK cell attack by
60-73% at effector to target cell ratios of 5:1 and 2.5:1. The
resistance to killing by rIL2 activated lymphocytes was
considerably less and in the range 12.5-42% in two
experiments, while the least resistance, ranging from 3.4-
24.6%, was presented to killer cells activated with a
combination of rIL2 and rTNF-alpha.
Discussion
The results demonstrate that there is no correlation between
the levels of NK cell killing of K562 and MPCa by the PBL
of the different individuals examined. There are also
differential changes in activity against these two targets in
response to rIL2 activation (Table I). This would suggest
that different lytic mechanisms may be operating against
these two targets, possibly via different effector cell
populations. There is also no correlation between the cyto-
toxic capacity of the PBL and their potential to inhibit the
proliferation of tumour target cells. This indicates that
different mechanisms are involved in cytotoxicity and cyto-
stasis, which is another multi-effector function mediated by
several lymphocyte subsets (Matossian-Rogers & Taidi,
1983). In the present experiments whole peripheral blood
mononuclear cells containing monocytes were used and these
can potentially contribute to cytotoxic and cytostatic
reactions; we have, however, used these terms operationally
to define a function rather than a particular cell type.
Successful immunotherapeutic procedures must aim to
enhance both these effector systems.
Treatment of PBL with rIL2 did not improve the cyto-
toxic potential of all patients' lymphocytes. In fact the
cytotoxic capacity of five out of eight samples remained
either unaltered or deteriorated after 3 days' culture with
rIL2 (Table I). The generation of cytotoxic capacity in IL2-
stimulated PBL is not only dependent on IL2 but also on the
interaction of other lymphokines and cytokines produced by
the stimulated cells. Large variations in the production of
interferon-gamma, TNF-beta and TNF-alpha by IL2
stimulated PBL from different donors have been reported
(Meager et al., 1987).
Recent experiments demonstrate that the extent of
activation of NK cells by exposure to IL2 is variable and
donor-dependent (Titus et al., 1987). This is possibly due to
the different levels of synergising cytokines produced in
response to IL2 by different donors. The results of Meager
et al. (1987) demonstrate that production of TNF-beta by
PBL was only weakly enhanced by rIL2 stimulation and in
some donors TNF-alpha levels of rIL2-stimulated cultures576 A. MATOSSIAN-ROGERS et al.
Table IV Cytotoxicity of rIL2- and rIL2+rTNF-a activated LAK cells against natural killer cell selected (NKCS) K562 target
cells
Treatment of effector lymphocytes (% specific 51Cr-release from targets at effector to target ratios)
Nil rIL2 rIL2+rTNF-a
Exp. Target
no. cells 5:1 2.5:1 5:1 2.5:1 5:1 2.5:1
1 K562 27.3 15.0 38.0 20.0 48.6 24.8
K562-NKCS 10.9 (60.1)a 4.4 (70.7) 22.0 (42.2) 11.9 (40.5) 39.3 (19.2) 18.7 (24.6)
2 K562 24.5 12.6 69.1 45.6 71.4 48.9
K562-NKCS 6.7 (72.7) 3.4 (73.1) 52.9 (23.5) 39.9 (12.5) 68.3 (4.4) 47.1 (3.7)
aPercentage resistance to killing calculated according to the formula:
100[%specific release fromK562-NKCSx 100 [ % specific release from K562
J
were lower than those of unstimulated cultures. TNF-alpha
has numerous immunomodulatory effects which include the
enhancement of cytotoxicity in monocytes (Philip & Epstein,
1986), the induction of IL2 receptors on CD16+ large
granular lymphocytes (0tensen et al., 1987) and ILI pro-
duction by human monocytes and endothelial cells
(Dinarello et al., 1986).
In our experiments the incubation of patients' PBL with
rIL2 and additional rTNF-alpha endowed the non- or low-
responders to rIL2 with high levels of cytotoxic capacity
(Table I). PBL which showed a strong response to rIL2 were
not affected significantly by additional exposure to rTNF-
alpha. Culture of PBL with rTNF-alpha alone did not
induce strong cytotoxic capacity in any of the samples tested
(data not shown). Apart from the increased expression of
receptors for IL2 induced by TNF-alpha the induction of
peripheral blood mononuclear cells to secrete ILl may have
a role in the enhanced killing capacity bf the patients'
lymphocytes. Cytotoxic activity of large granular lympllo-
cytes has been shown to be closely related to ILl pro-
duction. Monocytes from patients with malignant disease
have been shown to be defective in ILl production and have
depressed NK cell activity (Son et al., 1982; Herman et al.,
1984). Herman et al. (1985) demonstrated that K562 target
cells treated with ILI bound greater numbers of LGL than
untreated target cells and defective cytotoxicity of LGL from
patients with hepatocellular carcinoma could be corrected by
treating the target K562 cells with ILI.
TNF-alpha used in combination with rIL2 not only
improved the cytotoxic capacity of LAK cells but also their
capacity to prevent the proliferation of the target cells (Table
II). Cytotoxicity of tumour targets even at high effector
to target cell ratios is rarely complete and surviving tumour
cells can proliferate. Our results demonstrate that K562
target cells which survived NK cell cytotoxicity and grew out
(K562 NKCS) are 60-73% more resistant to NK cells than
the parent K562 population (Table IV). Similar results were
obtained with K562, which survived killing by LAK cells
(data not shown). It is thus important that LAK cells exert a
cytostatic effect on tumour cells as well as being cytolytic.
rTNF-alpha used in addition to rIL2 to generate LAK cell
activity increased the cytostatic activity against K562 of all
samples of PBL tested. Suzuki et al. (1987) demonstrated
that tumour cells remained dormant in the peritoneal cavity
of immune mice due to the cytostatic action of host cells
induced by the synergistic action of IFN-gamma and
TNF-alpha.
It appears that effector cells activated by the use of rIL2
and rTNF-alpha are more aggressive killers and also
cytostatic. Phenotypic analysis of comparable cultures of
LAK cells activated by rIL2 in combination with rTNF-
alpha showed no differences in these cell populations (data
not shown). There were also no differences in cell numbers,
indicating that there was no differential outgrowth of cell
subsets (data not shown). The enhanced killing capacity of
rIL2+rTNF-alpha-LAK cells may be due to a combination
of factors, such as the induction of ILl production, the
increased expression of IL2 receptors and other immuno-
regulatory effects of TNF-alpha on lymphocytes and mono-
cytes, such as the induction of the synthesis of novel lytic or
cytostatic proteins (Ruggiero et al., 1987). Another
possibility is the recognition of a broader spectrum of targets
on tumour cells by rIL2+rTNF-alpha-LAK cells than by
those activated by rIL2 alone. K562 target cells which
survived killing by NK cells expressed a decreasing order of
resistance to subsequent killing by NK, rIL2-LAK and
rIL2+rTNF-alpha-LAK cells (Table IV). One can postulate
that rIL2-LAK cells recognise NK cell targets as well as
another set of determinants while rIL2+rTNF-alpha-LAK
cells recognise both these sets of targets and also a third
family of target structures on tumour cells. Whatever the
mechanism of the improved performance of rIL2+rTNF-
alpha-LAK cells it is apparent that the additional use of
rTNF-alpha in the preparation of LAK cells from PBL or
splenocytes could improve the success rate of LAK cell
immunotherapy.
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